These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 36465246)

  • 1. Retracted: Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients' Quality of Life and Adverse Reaction Rate.
    Engineering JOH
    J Healthc Eng; 2022; 2022():9834370. PubMed ID: 36465246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients' Quality of Life and Adverse Reaction Rate.
    Ma Z; Wang Y; Sun Y; Lin G; Zhao Z
    J Healthc Eng; 2022; 2022():7898737. PubMed ID: 35310186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Efficacy of Crizotinib in Advanced ALK Positive 
Non-small Cell Lung Cancer].
    Zhao J; Zhang K; Zhang L; Wang H
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):616-20. PubMed ID: 26483333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma.
    Zhang Q; Qin N; Wang J; Lv J; Yang X; Li X; Nong J; Zhang H; Zhang X; Wu Y; Zhang S
    Thorac Cancer; 2016 Jan; 7(1):3-8. PubMed ID: 26816533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
    Shaw AT; Kim DW; Nakagawa K; Seto T; Crinó L; Ahn MJ; De Pas T; Besse B; Solomon BJ; Blackhall F; Wu YL; Thomas M; O'Byrne KJ; Moro-Sibilot D; Camidge DR; Mok T; Hirsh V; Riely GJ; Iyer S; Tassell V; Polli A; Wilner KD; Jänne PA
    N Engl J Med; 2013 Jun; 368(25):2385-94. PubMed ID: 23724913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J
    BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
    Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
    N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retracted: Effects of Camrelizumab Combined with First-Line Chemotherapy on Serum SCC, VEGF Levels, and Adverse Reactions in Patients with Advanced Squamous Cell Carcinoma of the Lung.
    Intelligence And Neuroscience C
    Comput Intell Neurosci; 2023; 2023():9879124. PubMed ID: 37502038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
    Nishio M; Kim DW; Wu YL; Nakagawa K; Solomon BJ; Shaw AT; Hashigaki S; Ohki E; Usari T; Paolini J; Polli A; Wilner KD; Mok T
    Cancer Res Treat; 2018 Jul; 50(3):691-700. PubMed ID: 28701030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retracted: Effects of ADOPT-Based Breathing Training Combined with Continuous Nursing on Quality of Life, Mental Health, and Self-Efficacy in Lung Cancer Patients Undergoing Chemotherapy: Based on a Retrospective Cohort Study.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9798781. PubMed ID: 37416158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retracted: The Combined Clinical Efficacy and Safety Analysis of Adoptive Immunotherapy with Radiotherapy and Chemotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.
    And Biomechanics AB
    Appl Bionics Biomech; 2023; 2023():9873947. PubMed ID: 37829524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
    Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
    Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
    Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW
    BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retracted: Safety and Efficacy of Mild Moxibustion on Cancer-Related Fatigue in Non-Small-Cell Lung Cancer Patients Undergoing Chemotherapy.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9891649. PubMed ID: 37503404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retracted: Analysis on the Efficacy of Bronchial Artery Chemoembolization Combined with 125I Seed Implantation in the Therapy of Advanced Non-Small-Cell Lung Cancer Based on the Medical Database.
    International BR
    Biomed Res Int; 2023; 2023():9765786. PubMed ID: 38075311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9826952. PubMed ID: 37387848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retracted: Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9820926. PubMed ID: 38125182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
    Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
    Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.
    Frampton JE
    Drugs; 2013 Dec; 73(18):2031-51. PubMed ID: 24288180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.